Application of GLUL biomarker in diagnosis, treatment or prognosis prediction of heart failure

By using GLUL and its enhancer to regulate cardiomyocyte function, the problem of limited efficacy in heart failure treatment is solved, and more accurate diagnosis and prediction of heart failure is achieved, and cardiac function is significantly improved.

CN118949035APending Publication Date: 2024-11-15PEKING UNIVERSITY FIRST HOSPITAL (PEKING UNIVERSITY FIRST CLINICAL MEDICAL COLLEGE)
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202411043109.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-31
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

The existing treatment methods for heart failure are limited in effect, lack of effective gene therapy drugs, and existing biomarkers are insufficient in diagnosis and prognosis prediction, making it difficult to accurately prevent and relieve heart failure.

Method used

Glutamine synthase (GLUL) and its enhancer are used as pharmaceutical compositions to prevent, relieve or Treat heart failure and assist in the diagnosis and prediction of heart failure by detecting GLUL markers.

Benefits of technology

Significantly improves heart failure and cardiac fibrosis after myocardial infarction, prolongs the metabolic level of cardiomyocytes, provides more accurate diagnosis and prognosis prediction of heart failure, and enhances therapeutic effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118949035A_ABST
    Figure CN118949035A_ABST
Patent Text Reader

Abstract

The invention discloses application of a GLUL biomarker in diagnosis, treatment or prognosis prediction of heart failure. The level of glutamine synthetase (GLUL) in heart tissues and plasma of heart failure people and heart failure mouse models is reduced. The targeted heart overexpression GLUL in a mouse body can improve the cardiac function and cardiac fibrosis after myocardial infarction. In-vitro experiments show that cell autophagy can be aggravated and the mitochondrial metabolism level of myocardial cells can be reduced by knocking out the GLUL.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biotechnology and relates to the application of GLUL biomarkers in the diagnosis, treatment or prognosis prediction of heart failure. Background Art

[0002] Heart failure refers to the heart's ability to pump blood below normal levels. It is a clinical syndrome that may occur when various heart diseases develop to a certain stage. Myocardial infarction is one of the most important causes of heart failure. Heart failure caused by myocardial infarction is clinically referred to as ischemic cardiomyopathy.

[0003] BNP is used clinically to detect the degree of heart failure in patients. At the same time, the new clinical drug recombinant human brain natriuretic peptide (rhBNP, Neosusceptor) can promote renal excretion of water and sodium, dilate blood vessels to lower blood pressure, reduce cardiac preload and afterload, inhibit the adrenaline system, thereby delaying myocardial remodeling and maintaining hemodynamic stability. Although Neosusceptor alone or in combination has been reported to help improve the symptoms and prognosis of patients with heart failure, the degree of treatment is still limited, and there is no gene therapy drug on the market, so the development of new drugs for heart failure is urgently needed.

[0004] Traditional heart failure treatments include: drugs that help relieve symptoms, such as diuretics, vasodilators, or digoxin; drugs that help prolong survival: angiotensin-converting enzyme (ACE) inhibitors, beta-blockers, aldosterone antagonists, angiotensin II receptor blockers (ARBs), angiotensin receptor / neprilysin inhibitors (ARNIs), sodium-glucose co-transporter 2 inhibitors (SGLT2), or sinus node inhibitors. Summary of the invention

[0005] In order to solve the technical problems existing in the prior art, the present invention provides the following technical solutions:

[0006] The present invention provides the use of GLUL or an enhancer thereof in preparing a pharmaceutical composition for preventing, alleviating or treating heart failure.

[0007] Furthermore, the pharmaceutical composition is administered orally, via suppository, around a lesion, on a lesion surface, topically, intravenously, parenterally, intraperitoneally, intramuscularly, intralesionally, intrathecally, intranasally or subcutaneously.

[0008] Furthermore, the pharmaceutical composition can be administered intravenously, intraperitoneally, intramuscularly, or intralesionally after preparation.

[0009] Furthermore, the individuals include human and / or non-human individuals.

[0010] Furthermore, the individual is a human.

[0011] Furthermore, the GLUL prevents, alleviates or treats heart failure by regulating autophagy of cardiomyocytes, mitochondrial superoxide, mitochondrial complex I protein, myocardial hypertrophy, cardiac fibrosis and cardiac ejection capacity.

[0012] Furthermore, the enhancer of GLUL enhances the function or unit effective time of GLUL by enhancing the unit activity of GLUL or preventing or reducing the degradation of GLUL.

[0013] Furthermore, the heart failure includes heart failure caused by hypertension, heart failure caused by coronary artery disease, heart failure caused by valvular heart disease, heart failure caused by myocarditis, heart failure caused by congenital heart disease, heart failure caused by arrhythmia, heart failure caused by diabetes, heart failure caused by abnormal thyroid function, heart failure caused by myocardial infarction, and heart failure caused by chronic anemia.

[0014] The term "heart failure" is well known to the skilled person. As used herein, the term preferably relates to impaired systolic and / or diastolic function of the heart known to those skilled in the art with obvious signs of heart failure. Preferably, heart failure as referred to herein may be "acute" (rapid, sudden onset) or "chronic" (recognized recurrent symptoms). Heart failure according to the present invention includes overt and / or advanced heart failure. In overt heart failure, the subject exhibits symptoms of heart failure known to those skilled in the art.

[0015] According to the NYHA (New York Heart Association) classification, patients with heart failure are classified as belonging to NYHA I, NYHA II, NYHA III, and NYHA IV classes. Patients with heart failure already have structural and functional changes in the pericardium, myocardium, coronary circulation, or heart valves. He will not be able to fully recover and will require treatment. Patients with NYHA I class have no obvious symptoms of cardiovascular disease, but there is already objective evidence of functional impairment. NYHA II class patients have slight limitations in physical activity. NYHA III class patients show significant limitations in physical activity. NYHA IV class patients are unable to perform any physical activity without discomfort. They show symptoms of cardiac insufficiency at rest.

[0016] This functional classification is supplemented by the latest classification of the American College of Cardiology and the American Heart Association (see J.Am.Coll.Cardiol.2001;38;2101-2113, updated in 2005, see J.Am.Coll.Cardiol.2005;46;e1-e82). Four stages A, B, C and D are defined. Stages A and B are not heart failure, but are considered to assist in early identification of patients before the development of "real" heart failure. It is best to define stage A and B patients as patients with risk factors for the development of heart failure. For example, patients with coronary artery disease, hypertension or diabetes who have not yet shown impaired left ventricular (LV) function, hypertrophy or geometric cavity malformation will be considered stage A, while patients who are asymptomatic but show LV hypertrophy and / or impaired LV function will be designated as stage B. Stage C represents patients with current or past symptoms of heart failure related to underlying structural heart disease (most patients have heart failure), while stage D represents patients with true refractory heart failure.

[0017] At least one abnormality of cardiac structure or function associated with heart failure is preferably selected from functional and / or structural damage to the myocardium, epicardium, valves or coronary circulation; impaired pumping or filling capacity, usually systolic or diastolic dysfunction; altered geometry of the left ventricle; hypertension associated with geometric chamber malformations; left ventricular hypertrophy; altered left ventricular structure with or without left ventricular hypertrophy; increased septal diameter; increased posterior wall diameter, concentric myocardial enlargement, eccentric myocardial enlargement, left ventricular diastolic dysfunction.

[0018] The present invention provides a pharmaceutical composition for preventing, alleviating or treating heart failure, comprising an effective amount of GLUL or an enhancer thereof for preventing, alleviating or treating heart failure.

[0019] The term "effective amount" used in the present invention refers to an amount of a drug that is effective in treating a disease or condition in a mammal alone or in combination with other drugs or treatment regimens. In the case of heart failure, a preventive, alleviating or therapeutically effective amount of a pharmaceutical composition can reduce functional and / or structural damage to the myocardium, epicardium, valve or coronary circulation; reduce impaired pumping or filling capacity; improve systolic or diastolic dysfunction; reduce changes in the geometry of the left ventricle; reduce or eliminate hypertension associated with geometric cavity deformities; reduce or eliminate left ventricular hypertrophy; reduce or eliminate symptoms of left ventricular structural changes with or without left ventricular hypertrophy; reduce septum diameter; reduce posterior wall diameter, reduce concentric myocardium, reduce eccentric myocardium, and alleviate or eliminate left ventricular diastolic dysfunction.

[0020] Furthermore, the pharmaceutical composition also includes other drugs for treating heart failure.

[0021] Furthermore, the other heart failure treatment drugs include diuretics, vasodilators or digoxin, angiotensin converting enzyme (ACE) inhibitors, beta-blockers, aldosterone antagonists, angiotensin II receptor blockers (ARBs), angiotensin receptor / neprilysin inhibitors (ARNIs), sodium-glucose co-transporter 2 inhibitors (SGLT2) or sinus node inhibitors.

[0022] Furthermore, the pharmaceutical composition includes pharmaceutically acceptable excipients.

[0023] The term "pharmaceutically acceptable" as used herein designates a carrier that is generally chemically and / or physically compatible with the other ingredients making up the formulation and physiologically compatible with the recipient thereof. Pharmaceutically acceptable adjuvants used in the vaccine compositions of the present invention may include, but are not limited to, for example, pharmaceutically acceptable liquids, gels or solid carriers, aqueous vehicles (e.g., sodium chloride injection, Ringer's injection, isotonic dextrose injection, sterile water injection or Ringer's dextrose and lactate injection), non-aqueous vehicles (e.g., non-volatile oils of plant origin, cottonseed oil, corn oil, sesame oil or peanut oil), antimicrobial agents, isotonic agents (e.g., sodium chloride or dextrose), buffers (e.g., phosphate or citrate buffer), antioxidants (e.g., sodium bisulfate), anesthetics (e.g., procaine hydrochloride), suspending / dispersing agents (e.g., sodium carboxymethylcellulose, hydroxypropyl methylcellulose or polyvinylpyrrolidone), chelating agents (e.g., EDTA (ethylenediaminetetraacetic acid) or EGTA (ethylene glycol tetraacetic acid)), emulsifiers (e.g., polysorbate 80 (Tween 80)), diluents, adjuvants, excipients, or non-toxic auxiliary substances, other components known in the art, or various combinations thereof.

[0024] Furthermore, the auxiliary materials include glidants, sweeteners, diluents, preservatives, colorants, flavor enhancers, surfactants, wetting agents, dispersants, suspending agents, stabilizers, isotonic agents, pH regulators and / or buffers, and emulsifiers.

[0025] Furthermore, the GLUL in the pharmaceutical composition includes its protein or protein derivative, and the protein derivative includes a pharmaceutically acceptable salt.

[0026] Furthermore, the pharmaceutically acceptable salts include acid addition salts and base addition salts.

[0027] Further, the acid addition salt includes, but is not limited to, any one of the hydrochloride, hydrobromide, hydroiodide, phosphate, sulfate, nitrate, ethanesulfonate, toluenesulfonate, benzenesulfonate, acetate, maleate, tartrate, succinate, citrate, benzoate, ascorbate and salicylate, malonate, adipate, caproate, argininate, fumarate, nicotinate, phthalate or oxalate of FTY720, or a combination of at least two thereof.

[0028] Furthermore, the base addition salt includes but is not limited to lithium salt, sodium salt, potassium salt, barium salt, calcium salt, magnesium salt, aluminum salt, iron salt, ferrous salt, copper salt, zinc salt of FTY720, or a salt of FTY720 with morpholine, diethylamine, triethylamine, isopropylamine, trimethylamine, lysine or histidine.

[0029] Furthermore, the pharmaceutically acceptable salt is obtained from an acid, which includes an organic acid or an inorganic acid.

[0030] Furthermore, the inorganic acid includes hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, and phosphoric acid.

[0031] Furthermore, the organic acid may be formic acid, acetic acid, maleic acid, succinic acid, mandelic acid, fumaric acid, malonic acid, pyruvic acid, oxalic acid, glycolic acid, salicylic acid, pyranosidyl acid, α-hydroxy acid such as citric acid or tartaric acid, amino acid, aromatic acid, or sulfonic acid.

[0032] Furthermore, the pharmaceutically acceptable salts include base addition salts, specifically alkali metal salts (such as sodium salts, potassium salts, etc.) and alkaline earth metal salts (such as calcium salts, magnesium salts, etc.).

[0033] Any pharmaceutical composition encompassed in this application can be delivered orally, for example, via any acceptable and suitable oral formulation. Exemplary oral formulations include, but are not limited to, for example, tablets, lozenges, pastilles, aqueous and oily suspensions, dispersible powders or granules, emulsions, hard and soft capsules, liquid capsules, syrups, and elixirs. Pharmaceutical compositions intended for oral administration can be prepared according to any method known in the art for making pharmaceutical compositions intended for oral administration.

[0034] The present invention provides the use of a substance for detecting GLUL markers in a sample in preparing a product for diagnosing or prognosing heart failure.

[0035] Furthermore, the sample includes blood, plasma, serum, saliva, urine, feces, cerebrospinal fluid, semen, vaginal secretions, sputum, sweat, breast milk, synovial fluid, mucus, tears, bile, gastric juice, interstitial fluid, tissue biopsy or epithelial cells, oral swab, nasal swab, aqueous humor, amniotic fluid, pleural fluid or the subject's exhaled breath.

[0036] Furthermore, the sample includes blood, plasma, serum, tissue biopsy or epithelial cells.

[0037] Furthermore, the sample is plasma.

[0038] Furthermore, the sample is blood.

[0039] In some embodiments, the sample is taken directly from the subject without further processing, for example, blood can be obtained from the subject's peripheral circulatory system (e.g., via a blood collection needle). The sample may include, for example, blood, urine, feces, saliva, cerebrospinal fluid, and sweat. Non-limiting examples of such samples include blood (or components of blood - e.g., white blood cells, red blood cells, platelets) obtained from any anatomical location of a subject (e.g., tissue, circulatory system, bone marrow), cells obtained from any anatomical location of a subject, skin, heart, lung, kidney, exhaled breath, bone marrow, stool, semen, vaginal fluid, tissue fluid from tumor tissue, breast, pancreas, cerebrospinal fluid, tissue, throat swab, biopsy, placental fluid, amniotic fluid, liver, muscle, smooth muscle, bladder, gallbladder, colon, intestine, brain, cavity fluid, sputum, pus, microbiota, meconium, breast milk, prostate, esophagus, thyroid, serum, saliva, urine, gastric and digestive fluids, tears, ocular fluids, sweat, mucus, earwax, oils, glandular secretions, cerebrospinal fluid, hair, nails, skin cells, plasma, nasal swab or nasopharyngeal wash, cerebrospinal fluid, umbilical cord blood, lymphatic fluid, and / or other excreta or body tissues.

[0040] The present invention provides a product, which comprises a substance for detecting GLUL markers.

[0041] Furthermore, the product includes a product for diagnosing or assisting in diagnosing whether a sample to be tested is a heart failure sample, a product for diagnosing or assisting in diagnosing whether a subject to be tested is a heart failure patient, a product for predicting or assisting in predicting whether a sample to be tested is a heart failure sample, and a product for predicting or assisting in predicting whether a subject to be tested is a heart failure patient.

[0042] Furthermore, the substance for detecting GLUL markers includes a substance for detecting gene expression levels or a substance for detecting protein levels.

[0043] Furthermore, the products include reagents, test kits, test strips, nucleic acid membrane strips, chips, primers, and probes.

[0044] Furthermore, the subject includes a human or a non-human mammal.

[0045] Furthermore, the reagents include reagents for detecting the presence, absence and / or amount of GLUL genes, fragments and proteins in a sample by PCR reaction, RT-PCR derivatization reaction, 3SR amplification, LCR, SDA, NASBA, TMA, SYBR Green, TaqMan probe, molecular beacon, double hybridization probe, composite probe, ISH, microarray, Southern blot, Northern blot, multi-analyte spectrum test, enzyme-linked immunosorbent assay (ELISA), radioimmunoassay, immunofluorescence assay, enzyme immunoassay, immunoprecipitation assay, chemiluminescence assay, immunohistochemistry assay, dot blot assay or slot blot assay.

[0046] Furthermore, the kit includes a gene detection kit and a protein detection kit.

[0047] Furthermore, the gene detection kit includes primers, reagents or chips for detecting the transcription level of the GLUL gene.

[0048] Furthermore, the protein detection kit includes reagents, chips, antibodies, and ligands for detecting the protein level of GLUL expression.

[0049] The term "level of expression" or "expression level" generally refers to the amount of a biomarker in a biological sample. "Expression" generally refers to the process by which information (e.g., genetic coding and / or epigenetic information) is converted into structures that exist and function in a cell. Therefore, as used herein, "expression" may refer to transcription into polynucleotides, translation into polypeptides, or even polynucleotide and / or polypeptide modifications (e.g., post-translational modifications of polypeptides). Fragments of transcribed polynucleotides, translated polypeptides, or polynucleotide and / or polypeptide modifications (e.g., post-translational modifications of polypeptides) should also be considered expressed, whether they are derived from transcripts generated by alternative splicing or degraded transcripts, or from post-translational processing of polypeptides (e.g., by proteolysis). "Expressed genes" include genes that are transcribed into polynucleotides (e.g., mRNA) and then translated into polypeptides, as well as genes that are transcribed into RNA but not translated into polypeptides (e.g., transport and ribosomal RNA).

[0050] In some embodiments, increased expression," "increased expression level," "increased level," "elevated expression," "elevated expression level," or "elevated level" refers to increased expression or increased level of a biomarker in an individual relative to a control, such as an individual without a disease or disorder (e.g., cancer), an internal control (e.g., a housekeeping biomarker), or the median expression level of the biomarker in a sample from a patient group / population.

[0051] In some embodiments, "reduced expression", "reduced expression level", "reduced level", "lowered expression", "reduced expression level" or "reduced level" refers to decreased expression or decreased level of a biomarker in an individual relative to a control, such as an individual without a disease or disorder (e.g., cancer) or an internal control (e.g., a housekeeping biomarker), or the median expression level of the biomarker in a sample from a patient group / population. In some embodiments, decreased expression is little expression or no expression.

[0052] The term "kit" used in the present invention is any article (e.g., package or container) comprising at least one reagent (e.g., a drug for treating a condition or a probe for specifically detecting an analyte of the present invention). The kit is preferably promoted, distributed or sold in the form of a unit for performing the method of the present invention. Typically, the kit may further include a separated carrier device to receive one or more container devices, such as vials, tubes, etc., in a closed space. In particular, the container device may include one of the individual elements to be used in the method of the first aspect. The kit may further include one or more other containers, containing other materials, including but not limited to buffers, diluents, filters, needles, syringes, and package inserts with instructions for use. A label may be present on the container to indicate that the composition is used for a specific purpose, and may also indicate guidelines for in vivo or in vitro use.

[0053] The term "GLUL" as used herein is intended to encompass fragments, variants (e.g., allelic variants), and derivatives thereof. Representative human GLUL cDNA and human GLUL protein sequences are well known in the art and are publicly available from the NCBI website. For example, at least one human GLUL isoform is known: human GLUL, Gene ID: 2752. Nucleic acid and polypeptide sequences of GLUL orthologs in organisms other than humans are well known.

[0054] The present invention provides a method for screening drugs for treating, preventing or alleviating heart failure for non-therapeutic purposes, the method comprising the step of applying candidate drugs to in vitro myocardial cells or tissues, and detecting the expression of GLUL after the candidate drugs are administered.

[0055] Furthermore, the expression of GLUL includes the transcription level of the GLUL gene or the protein level of GLUL.

[0056] Advantages and beneficial effects of the present invention:

[0057] The present invention uses the GLUL marker as a biomarker for the diagnosis, treatment or prognosis prediction of heart failure, and has a significant effect on the diagnosis, treatment or prognosis prediction of heart failure. The level of glutamine synthetase (GLUL) is reduced in the heart tissue and plasma of people with heart failure and heart failure mouse models. Targeted heart overexpression of GLUL in mice can improve heart failure and cardiac fibrosis after myocardial infarction. In vitro experiments show that knocking out GLUL will aggravate cell autophagy and reduce the level of mitochondrial metabolism in cardiomyocytes. BRIEF DESCRIPTION OF THE DRAWINGS

[0058] Figure 1 This is the result of screening the gene module negatively correlated with heart failure phenotype in GEO database GSE5406 using bioinformatics WGCNA method;

[0059] Figure 2 It is the volcano map, heat map, GO enrichment analysis, KEGG enrichment analysis, and GSEA enrichment analysis result map of differentially expressed genes in the GSE5406 dataset;

[0060] Figure 3 The important differentially expressed genes screened by the WGCNA algorithm and the mRNA level and ROC curve results of GLUL are shown;

[0061] Figure 4 This is a statistical result chart of GLUL levels in peripheral blood transcriptome data of GSE123342 myocardial infarction patients at baseline and 30 days and 1 year after myocardial infarction;

[0062] Figure 5 It is a graph of the ELISA test results of GLUL in the collected samples;

[0063] Figure 6 It is the single cell map in the single cell dataset GSE145154, the UMAP map of 7 cell types, the corresponding marker gene dot map of 7 types of cells, and the expression heat map of 7 types of cell marker genes;

[0064] Figure 7 It is the UMAP map of cardiomyocyte marker genes in the single-cell database GSE145154, the violin plot of the differential expression of GLUL genes in the infarcted and non-infarcted areas of failing hearts in seven cell types, the volcano plot of differential gene expression in cardiomyocytes, and the volcano plot of differential gene expression in endothelial cells;

[0065] Figure 8The figures are the heart failure model after myocardial infarction in mice and the results of western blot detection of GLUL, wherein A is the heart failure model after myocardial infarction in mice, B is the GLUL level in the heart tissue of the heart failure model mice and the control mice detected by the western blot method at the protein level, C is the statistical result figure of B, D is the GLUL level in the plasma of the heart failure model mice and the control mice detected by the western blot method at the protein level, and E is the statistical result figure of D and the result figure of total protein Ponceau red staining of D;

[0066] Fig. 9 The left ventricular ejection fraction (LVEF), left ventricular shortening fraction (LVFS), left ventricular end-diastolic volume (LVEDV), left ventricular end-systolic volume (LVESV) of the control group and the experimental group of mice treated with GLUL-AAV9 virus containing the promoter TNNT2 (targeting the heart), the echocardiogram results of mice with heart failure 4 weeks after myocardial infarction, the heart weight (HW) collected 4 weeks ago, the heart body weight ratio (HW / BW), the heart tibia length ratio (HW / TL), WGA staining, GLUL immunofluorescence, HE, Masson, Sirius red staining results;

[0067] Fig.10 It is the GO enrichment analysis of differentially expressed genes between rat primary cardiomyocytes treated with GLUL-siRNA and the control group, the results of immunoblotting, the results of electron microscopy, and the results of immunofluorescence;

[0068] Fig.11 This is the Seahorse result of rat primary cardiomyocytes treated with GLUL-siRNA / MSO. DETAILED DESCRIPTION

[0069] Example

[0070] 1. Experimental methods

[0071] 1.1 Bioinformatics analysis

[0072] The GSE5406 data set in the GEO database was retrieved, and the "WGCNA" package in the R language was used to screen important gene modules. First, the module soft threshold selection was performed, followed by sample clustering and clinical trait grouping, and then the network construction and module identification, as well as the association identification of modules with phenotypic data were completed. As a result, we obtained a statistically significant green module scatter plot (containing genes with decreased expression in the heart failure population) and a black module scatter plot (containing genes with decreased expression in the heart failure population), selected the green gene module with decreased expression in the heart failure population, and extracted all the genes in the module.

[0073] The “limma” package in R language was used for differential expression analysis, and volcano plots and heat maps were drawn. Secondly, the “ClusterProfiler” package was used for GO, KEGG, and GSEA enrichment analysis and display.

[0074] The extracted genes (1279) were intersected with the differentially expressed genes (40) with logFC>1 or <-1 on the online Venn diagram drawing website (Draw Venn Diagram (ugent.be)). The GLUL mRNA expression of each sample in the GSE5406 dataset was statistically analyzed using Prism9.0, and the ROC curve was drawn using the R language "pROC" package. The GLUL level in the peripheral blood transcriptome of patients with myocardial infarction at baseline and 30 days and 1 year after myocardial infarction (GSE123342) was statistically analyzed using Prism9.0. 100 patients with heart failure (ethics number: 2021 Scientific Research 100) were selected from the population hospitalized for coronary angiography in Peking University First Hospital, and 100 healthy control patients were matched. The baseline plasma was taken and tested using the human GLUL enzyme-linked immunosorbent assay (ELISA) kit (EIAab, E0162h) according to the instructions.

[0075] The single-cell sequencing data of the infarcted and non-infarcted areas in the failing hearts of heart failure patients in the single-cell dataset GSE145154 were selected for analysis, and the R language "Seurat" package was used to draw UMAP dimensionality reduction analysis diagrams, cell type UMAP diagrams, dot diagrams, heat maps and other visualization results.

[0076] The "Seurat" package was used in R language to draw UMAP maps of cardiomyocyte-related marker genes, violin plots of differential expression of GLUL in seven types of cells, and volcano plots of differentially expressed genes in cardiomyocytes and endothelial cells.

[0077] 1.2 Construction of GLUL-overexpressing AAV9 virus

[0078] 1.2.1 Construction of GLUL overexpression plasmid

[0079] Use PD564 plasmid as a template to insert the GLUL gene.

[0080] The restriction site is NotI+SalI, and the reaction system is shown in Table 1.

[0081] Table 1

[0082] DNA 3μg Enzyme (Notl) 0.5μL 10×Mix 3μL SalI 0.5μL <![CDATA[ddH2O]]> Up to 30 μL

[0083] The reaction procedure is shown in Table 2.

[0084] Table 2

[0085] 37℃ 2h 85℃ 20min 4℃ save

[0086] 2150 bp were cut off, and the product was 4020 bp.

[0087] The PCR reaction system is shown in Table 3.

[0088] Table 3

[0089] F Primer 1μl R Primer 0.5μL Mix 15μL DNA (PD564 template) 1 μg <![CDATA[ddH2O]]> Up to 30 μL

[0090] The primers used in PCR are shown in Table 4.

[0091] Table 4

[0092]

[0093] The PCR reaction program is shown in Table 5.

[0094] Table 5

[0095] Pre-denaturation 95℃ 3min transsexual 95℃ 30s annealing 55℃ 30s extend 72℃ 25s Fully extended 72℃ 5 save 12℃ hold

[0096] The reaction was repeated for 35 cycles.

[0097] The PCR product was subjected to agarose electrophoresis (1% agarose, 60 mL TAE, 6 Ul Gelstain) and gel recovery was performed (according to the instructions of the Agarose Gel DNA Recovery Kit (Enhanced) (DP219)).

[0098] After gel recovery, seamless cloning was performed, and the reaction system was shown in Table 6.

[0099] Table 6

[0100]

[0101]

[0102] The reaction system in Table 6 was incubated at 50°C for 15 min (1-2 fragments were inserted). If the subsequent operation cannot be performed immediately after the reaction is completed, the reaction sample can be stored at -20°C.

[0103] Transformation and clone identification:

[0104] a. Take 5 μl of the reaction sample from the previous step and add it to 50 μl of competent cells (note that the volume of the DNA sample added should not exceed 1 / 10 of the competent volume), mix gently, and place the mixture on ice for 30 min.

[0105] b. Heat shock in a 42°C water bath for 90 seconds, then quickly return to an ice bath and let stand for 3 to 5 minutes.

[0106] c. Add 500 μl of SOC or LB culture medium without antibiotics, mix gently, and culture at 37℃ with shaking for 1 hour. (Resuscitation of competent cells)

[0107] d. Centrifuge the bacterial solution at 5000 rpm for 1 minute to precipitate the bacteria. Aspirate most of the culture solution, leaving about 100 μl of the culture solution, and resuspend the bacteria. Then evenly spread all of it on an LB plate containing appropriate antibiotics and culture it in a 37°C incubator overnight.

[0108] e. On the second day, select clones on the plate for colony PCR or extract plasmids for enzyme digestion identification. You can also directly select several clones for sequencing identification.

[0109] The selected single clone was placed in 3 mL of LB medium containing ampicillin and shaken at 37°C for 16 h (no more than 18 h to prevent the ineffectiveness of ampicillin), and the plasmid was extracted (Tiangen Plasmid Extraction Kit, DP103), and Western blot / immunofluorescence was used to verify the success of overexpression.

[0110] 1.2.2 Addition of TNNT2 cardiac-specific promoter

[0111] The restriction enzyme cutting sites are: NotI+NheI. The reaction system is shown in Table 7.

[0112] Table 7

[0113] DNA 3μg Enzyme (Notl) 0.5μL 10×Mix 3μL NeA 0.5μL ddH2O Up to 30 μL

[0114] The PCR reaction system is shown in Table 8.

[0115] Table 8

[0116] F Primer 1μl R Primer 0.5μL Mix 15μL DNA (PD336 template) 1 μg <![CDATA[ddH2O]]> Up to 30 μL

[0117] The primers used in PCR are shown in Table 9.

[0118]

[0119] The seamless cloning reaction system is shown in Table 10.

[0120] Table 10

[0121]

[0122]

[0123] After sequencing was completed, the bacteria were shaken, plates were grown, and plasmids were extracted (Tiangen Plasmid Extraction Kit, DP103). A company (Paizhen Biotech) was sent to for AAV9 virus packaging.

[0124] 1.3 Animal model construction

[0125] Twelve 3-month-old mice were randomly divided into sham operation (SHAM), MI, and MI-GLUL-AAV9 groups. They were weighed and anesthetized by intraperitoneal injection of 1% sodium pentobarbital. Then, endotracheal intubation was performed and the mice were connected to an animal ventilator to maintain their breathing (respiratory ratio was 1:1, respiratory rate was 120 times / min, and tidal volume was 5 ml). The mice were fixed on a table and connected to ECG leads to record the ECG before and after ligation of the left anterior descending coronary artery. The skin of the chest and abdomen of the mice was prepared, the skin was opened between the 4th and 5th intercostal spaces of the sternum, the incision was 1-2 cm, and the muscles and pleural tissues were bluntly separated. The ribs and muscles were separated in the intercostal space with forceps, the incision was opened with a chest expander, and the pericardium was torn to fully expose the heart. A 6-0 ligature was used to pass through the myocardium from right to left 2-3 mm below the left atrial appendage, with a distance of 1 cm between the two needles, and the myocardium was ligated with a dead knot. The apex of the heart was observed to turn white, indicating that the ligation was successful. The chest cavity was directly closed in the myocardial infarction model and the epidermis was sutured.

[0126] The mice were subjected to electrocardiogram (ECG) detection. Using a BIOPAC recorder, the positive electrode head was inserted into the left hind limb of the mouse, the negative electrode head was inserted into the right upper limb of the mouse, and the black electrode head was inserted into the left upper limb of the mouse. The needle was inserted about 1-2 mm below the mouse skin. The software AcqKnowledge 5.0 was opened to detect the ECG waveform. After the mouse ECG was stable (baseline stability), 5 stable waveforms were recorded continuously. The ECG showed that the ST segment was significantly elevated. Then the chest cavity was closed and the epidermis was sutured. On the third day after myocardial infarction surgery, the MI-GLUL-AAV9 group of mice was injected with cardiac-specific GLUL overexpression AAV9 virus (5*10^11GC / mL) through the tail vein. Echocardiography was performed 4 weeks later. The mice were anesthetized with isoflurane, the chest hair was removed, and the body was facing up; the left ventricular short axis plane was detected using a VINNO6 ultrasound instrument (Suzhou Feiyinuo Company) with a 30MHz probe, and the anterior and posterior heart wall motion curves in the short axis papillary muscle plane were recorded using M-mode ultrasound. The parameters of the four cardiac cycles were continuously detected, and the left ventricular ejection fraction, left ventricular short axis shortening rate, left ventricular volume at end-systole, left ventricular volume at end-diastole, left ventricular posterior wall thickness at diastole, and left ventricular posterior wall thickness at systole were calculated. It was confirmed that the heart failure model of myocardial infarction mice was successfully established.

[0127] After 6 hours of fasting, blood was collected from the orbital vein of mice, centrifuged at 4000rpm for 10 minutes, and plasma samples were collected. The animals were anesthetized and killed by intraperitoneal injection of 1% sodium pentobarbital, the chest cavity was opened to expose the heart, the right atrial appendage was cut open, and the left ventricle was perfused with PBS; after perfusion, the heart was removed, the cardiac tissue under the papillary muscle plane was retained, the ischemic area (below the ligature) and the non-infarct area were separated and frozen in liquid nitrogen for Western immunoblotting detection. The remaining tissues were fixed in 4% paraformaldehyde for 24 hours, transferred to 20% sucrose for dehydration, embedded in OCT, and sliced ​​using a cryostat, and stained for GLUL immunofluorescence. Immunofluorescence staining: After the frozen sections were dried, they were fixed with 4% paraformaldehyde for 10 minutes. PBST was soaked 3 times, treated with TritonX-100 for 10 minutes, and blocked with 5% goat serum at room temperature for 30 minutes. The GLUL primary antibody was diluted with PBST buffer and incubated in a humidified box at 4°C overnight. The next day, the primary antibody was washed off, and after rinsing with PBST, the fluorescent secondary antibody diluted in PBST buffer was added and incubated at 37°C in the dark for 1 hour. PBST was soaked 3 times, and the nuclear dye DAPI was added to the slide. After sealing with a mounting agent, the slide was observed under a confocal fluorescence microscope and photographed to collect the experimental results. Another batch of fixed heart samples was sent to the company (Seville) for paraffin embedding and WGA, HE, Masson and Sirius red staining.

[0128] After the extracted plasma / tissue was placed on ice for 5 minutes, it was lysed in a lysis buffer containing protease inhibitors, centrifuged at 4°C, 12,000 rpm for 10 minutes, and the supernatant was aspirated into another pre-cooled clean centrifuge tube, and then the protein concentration was determined using a BCA kit. 5×SDS Loading Buffer was added at a ratio of 1 / 4 protein volume, and boiled at 100°C for 5 minutes to denature the protein. 1.5mm standard SDS-polyacrylamide separation gel and concentrated gel (5% concentrated gel and 10% separation gel) were prepared, and electrophoresis was performed after adding the protein sample. The PVDF membrane was activated by soaking it in methanol for a while, 4 filter papers and 2 sponges were soaked in transfer buffer, and sponge-filter paper-gel-PVDF membrane-filter paper-sponge were stacked in order, and the assembly was completed and placed in the transfer tank, and the sample was transferred to the PVDF membrane by 200mA constant current ice bath electrotransfer for 2 hours. 5% skim milk was used to seal for 1 hour. The membrane was incubated with primary antibodies overnight at 4°C (GLUL primary antibody, Abclonol; GAPDH primary antibody, Abmart), washed three times with PBST buffer, and incubated with goat anti-rabbit secondary antibody (Proteintech) at room temperature for 1 h. The membrane was developed using an ECL ultrasensitive chemiluminescence kit.

[0129] 1.4 GLUL knockout (siRNA) treatment

[0130] The siRNA sequences used for GLUL knockout are shown in Table 11.

[0131] Table 11

[0132] mGLUL-483-s (SEQ ID NO: 7) GAGGCACAUCUGUAAACGGAU(dT)(dT) mGLUL-483-a (SEQ ID NO: 8) AUCCGUUUACAGAUGUGCCUC(dT)(dT) mGLUL-900-s (SEQ ID NO: 9) CCAUACCAACUUCAGCACCAA(dT)(dT) mGLUL-900-a (SEQ ID NO: 10) UUGGUGCUGAAGUUGGUAUGG(dT)(dT) mGLUL-1242-s (SEQ ID NO: 11) CGAACCCUUCCAAUACAAGAA(dT)(dT) mGLUL-1242-a (SEQ ID NO: 12) UUCUUGUAUUGGAAGGGUUCG(dT)(dT)

[0133] Rats were treated as follows:

[0134] Extract rat primary cardiomyocytes. Use PBS to prepare enzymes, and prepare 80ml digestive solution (0.085g pancreatin, 0.045g collagenⅡ) for 50 newborn mice, filter and sterilize; prepare 3 large dishes and pour HBSS, cover two of them with lids for standby use, and place one on the right side close to the operation position; pour 75% alcohol in 1 large dish and place it on the left side close to the operation position; place 2 dish lids close to the operation position; take two well plate boxes and place them on the edge of the clean bench; catch the mouse, dip it in alcohol, cut from the second rib, cut open the chest cavity, squeeze out the heart, cut it and place it Place the heart in a large dish with HBSS; after the heart is completely cut off, transfer it to another large dish with HBSS and wash it for the second time; transfer the heart to a vial with a rotor, add a small amount of digestion solution, burn the scissors and cut the heart into pieces after cooling (not too pieces) to drain the blood; stir and digest at 37℃ for 6 minutes, and discard the digestion solution; add 8ml of digestion solution again, mix the cell mass, stir and digest at 37℃ for 6 minutes, and discard the digestion solution; add 7ml after cutting, and digest for 10 minutes; take a 15ml centrifuge tube, add 5mL Place DMEM on ice, add 5ml of digestion supernatant; add digestion solution, mix, digest for the second time at 37℃, 7min, repeat the previous step; add digestion solution, mix, digest for the third time at 37℃, 7min, repeat the previous step; digest for the 4th-5th time; collect 5 tubes of cells, centrifuge (1000rpm, RT 5min), discard the supernatant, resuspend, filter through a 100-mesh sieve into a 100ml beaker, wash the centrifuge tube with culture medium, plant it in 3 large dishes, and culture for 2h to allow fibroblasts to adhere to the wall; prepare 5-bromopropionate (0.307g dissolved in 100ml water, filtered and aliquoted and stored at -20℃) in advance, blow the cells in the dish into a 250ml bottle (3ml / mouse) to make up the volume, add 5-bromopropionate (1% volume), and blow quickly after adding to prevent local concentration from being too high, which is toxic to the cells; shake well, plant it into 4 24-well plates and a Seahorse In a 96-well plate, the density is generally greater than 10^6 cells / ml and can be processed after 48 hours.

[0135] When transfecting GLUL-siRNA, Opti-MEM I Reduced Serum Medium was used for cardiomyocyte culture. RNAiMAX (Invitrogen) transfection reagent was used to transfect the three designed siRNA sequences into cardiomyocytes. The medium was changed after 8 hours, RNA was extracted after 24 hours, and protein was extracted after 48-72 hours for subsequent qPCR and WB detection. RNA was extracted for transcriptome sequencing, protein was extracted for Western Blot detection, electron microscopy sample preparation and transmission electron microscopy detection (Peking University), live cell Mitotracker and MitoSOX staining, and Seahorse mitochondrial respiratory metabolism detection.

[0136] After adding glutamine synthetase inhibitors (MSO, MCE), live cell Mitotracker and MitoSOX staining, as well as Seahorse mitochondrial respiratory metabolism detection, were performed.

[0137] After treating cardiomyocytes in 96-well plates with angiotensin II (AngII, 10 ng / ml, MCE) to induce a cellular heart failure model, Lipo8000 was used to transfect GLUL overexpression plasmid, and Seahorse detection was performed 48 hours later.

[0138] 2. Experimental results

[0139] The gene modules (green modules) negatively correlated with the heart failure phenotype were screened in the GEO database GSE5406 using the bioinformatics WGCNA method. Figure 1 As shown, the module soft threshold is Figure 1 As shown in A, sample clustering and clinical trait grouping are as follows Figure 1 As shown in B, network construction and module identification are as follows Figure 1 C, the module is associated with the phenotypic data Figure 1 D. The results showed that bioinformatics screened out a gene module that was negatively correlated with the heart failure phenotype ( Figure 1 Green module in E, downregulated genes in heart failure population). Figure 1 F is a black module, which mainly shows the genes upregulated in heart failure population.

[0140] The selected genes were differentially expressed using the "limma" package in R language, and a volcano plot was performed ( Figure 2 A) and heat map ( Figure 2 B) and then the “ClusterProfiler” package was used to perform GO ( Figure 2 C) KEGG ( Figure 2 D) GSEA( Figure 2 E) Enrichment analysis, the results are as follows Figure 2The results showed that pathways such as "extracellular vesicle structure formation" and "autophagy" were enriched.

[0141] Will Figure 1 E The genes extracted from the green module (1279) and Figure 2 The intersection of the differentially expressed genes (40) with logFC>1 or <-1 in A yielded 9 important differentially expressed genes, and GLUL was one of them. The results are as follows Figure 3 A. The GLUL mRNA expression level of each sample in the GSE5406 dataset was statistically analyzed using Prism9.0. The results are shown in Figure 3 B. The ROC curve was drawn using the R language "pROC" package ( Figure 3 C). The results showed that the mRNA level of GLUL was significantly downregulated in patients with heart failure, and the ROC curve showed that the level of GLUL could well predict heart failure.

[0142] The GLUL levels (GSE123342) in the peripheral blood transcriptome of patients with myocardial infarction at baseline and 30 days and 1 year after myocardial infarction were statistically analyzed using Prism9.0. The results are as follows Figure 4 As shown, the results showed that GLUL levels decreased with the time of myocardial infarction.

[0143] 100 patients with heart failure (ethics number: 2021 Scientific Research 100) were selected from the population hospitalized for coronary angiography at Peking University First Hospital, and 100 healthy control patients were matched. The baseline plasma was taken and tested using the human GLUL enzyme-linked immunosorbent assay (ELISA) kit (EIAab, E0162h) according to the instructions. The results were as follows Figure 5 As shown, the results showed that GLUL levels were reduced in plasma of patients with heart failure.

[0144] The single-cell sequencing data of the infarcted and non-infarcted areas in the failing hearts of patients with heart failure in the single-cell dataset GSE145154 were selected for analysis. The results are as follows Figure 6 As shown in the figure, the results of UMAP dimensionality reduction analysis using the R language "Seurat" package are as follows Figure 6 As shown in A, the UMAP results of cell types are as follows Figure 6 As shown in B, the dot plot results are Figure 6 C shows the heat map results. Figure 6 As shown in D.

[0145] The single-cell dataset GSE145154 was selected for UMAP analysis of cardiomyocyte-related marker genes. The results are as follows: Figure 7 A. The differential expression of GLUL gene in seven types of cells was analyzed, and the violin plot is shown in Figure 7 B. Volcano plot of differentially expressed genes in cardiomyocytes and endothelial cells Figure 7 CD shown.

[0146] The process of constructing GLUL overexpression AAV9 virus is as follows Figure 8 As shown in the results, the 10-week-old C57BL / 6J male mice underwent myocardial infarction surgery, and the ejection fraction was less than 40% by echocardiography 4 weeks later, indicating that the heart failure mouse model was successfully established ( Figure 8 A). At this time, the mice were killed and plasma and heart samples were collected. The GLUL level in the heart tissue of heart failure model mice and control mice was detected at the protein level using the western blot method ( Figure 8 B), and its statistical graph is Figure 8 C. Western blot was used to detect the GLUL level in the plasma of heart failure model mice and control mice at the protein level ( Figure 8 D), the statistical graph and the total protein Ponceau red staining results are shown in Figure 8 E. The results showed that in the heart failure mouse model, the levels of GLUL in cardiac tissue and plasma were reduced.

[0147] The GLUL-AAV9 virus containing the promoter TNNT2 (targeting the heart) was constructed. The GLUL-AAV9 virus was injected into the tail vein of the experimental group of myocardial infarction model mice 3 days after surgery, while the control group was not injected with the virus. Four weeks later, the experimental and control group mice were subjected to echocardiography. The statistical results of the left ventricular ejection fraction (LVEF), left ventricular shortening fraction (LVFS), left ventricular end-diastolic volume (LVEDV), and left ventricular end-systolic volume (LVESV) of the control and experimental group mice are as follows Fig. 9 As shown in AD. Fig. 9 E is the echocardiogram of mice with heart failure 4 weeks after myocardial infarction in the control group and the experimental group; Fig. 9 FH is the heart weight (HW), heart-to-body weight ratio (HW / BW), and heart-to-tibia length ratio (HW / TL) of mice in the control and experimental groups at 4 weeks; Fig. 9 I represents the specific treatment result, and the results showed that in WGA staining, myocardial hypertrophy was improved in the GLUL-AAV9 treatment group; GLUL immunofluorescence suggested that GLUL was overexpressed in the GLUL-AAV9 treatment group; HE, Masson, and Sirius red staining suggested that the degree of cardiac fibrosis in the GLUL-AAV9 treatment group was alleviated compared with the myocardial infarction surgery control group.

[0148] Fig.10 GO enrichment analysis of differentially expressed genes between rat primary cardiomyocytes treated with GLUL-siRNA and the control group ( Fig.10 A) Western blot results ( Fig.10 B. Fig.10 D) Electron microscopy results ( Fig.10 C) Immunofluorescence results ( Fig.10 E), among which, GO enrichment analysis of differentially expressed genes in cardiomyocytes was enriched in the autophagy pathway; Western blotting results showed that the expression of autophagy-related genes and mitochondrial complex I proteins in primary cardiomyocytes of rats treated with GLUL-siRNA increased; electron microscopy results showed that autophagy increased in primary cardiomyocytes of rats treated with GLUL-siRNA; immunofluorescence results showed that mitochondrial superoxide increased significantly in primary cardiomyocytes of rats treated with GLUL-siRNA, and mitochondrial oxide increased slightly in cells treated with MSO (GLUL enzyme inhibitor).

[0149] Seahorse results show ( Fig.11 A), GLUL-siRNA / MSO-treated rat primary cardiomyocytes mitochondrial respiratory metabolism level decreased, and the statistical results are shown in Fig.11 As shown in B; Seahorse results showed that the mitochondrial metabolism level of heart failure model cells treated with GLUL overexpression plasmid increased, and the statistical results are as follows Fig.11 As shown in D.

[0150] In summary, the levels of glutamine synthetase (GLUL) are reduced in cardiac tissue and plasma of people with heart failure and heart failure mouse models. Targeted cardiac overexpression of GLUL in mice can improve cardiac function and cardiac fibrosis after myocardial infarction. In vitro experiments have shown that knocking out GLUL aggravates cell autophagy and reduces the level of mitochondrial metabolism in cardiomyocytes.

[0151] The description of the above embodiments is only used to understand the method and core idea of ​​the present invention. It should be pointed out that, for those skilled in the art, several improvements and modifications can be made to the present invention without departing from the principle of the present invention, and these improvements and modifications will also fall within the scope of protection of the claims of the present invention.

Claims

1. Use of GLUL or its enhancer in the preparation of a pharmaceutical composition for preventing, alleviating or treating heart failure.

2. The use according to claim 1, characterized in that The pharmaceutical composition is administered orally, by suppository, around the lesion, on the lesion surface, topically, intravenously, parenterally, intraperitoneally, intramuscularly, intralesionally, intrathecally, intranasally or subcutaneously; Preferably, the pharmaceutical composition is prepared and then administered intravenously, intraperitoneally, intramuscularly, or intralesionally; Preferably, the heart failure includes heart failure caused by hypertension, heart failure caused by coronary artery disease, heart failure caused by heart valve disease, heart failure caused by myocarditis, heart failure caused by congenital heart disease, heart failure caused by arrhythmia, heart failure caused by diabetes, heart failure caused by abnormal thyroid function, heart failure caused by myocardial infarction, and heart failure caused by chronic anemia; Preferably, the individuals include human and / or non-human individuals; Preferably, the individual is a human.

3. The use according to claim 1, characterized in that The GLUL prevents, alleviates or treats heart failure by regulating myocardial cell autophagy, mitochondrial superoxide, mitochondrial complex I protein, myocardial hypertrophy, cardiac fibrosis and cardiac ejection capacity; Preferably, the enhancer of GLUL enhances the function or unit effective time of GLUL by enhancing the unit activity of GLUL or preventing or reducing the degradation of GLUL.

4. A pharmaceutical composition for preventing, alleviating or treating heart failure, characterized in that: The pharmaceutical composition comprises an effective amount of GLUL or an enhancer thereof for prevention, alleviation or treatment.

5. The pharmaceutical composition according to claim 4, characterized in that The pharmaceutical composition includes pharmaceutically acceptable excipients; Preferably, the auxiliary materials include glidants, sweeteners, diluents, preservatives, colorants, flavor enhancers, surfactants, wetting agents, dispersants, suspending agents, stabilizers, isotonic agents, pH regulators and / or buffers, and emulsifiers; Preferably, the GLUL in the pharmaceutical composition comprises a protein or a protein derivative thereof, and the protein derivative comprises a pharmaceutically acceptable salt.

6. Use of substances for detecting GLUL markers in samples in the preparation of products for diagnosing or predicting the prognosis of heart failure.

7. The use according to claim 6, characterized in that The sample includes blood, plasma, serum, saliva, urine, feces, cerebrospinal fluid, semen, vaginal secretions, sputum, sweat, breast milk, synovial fluid, mucus, tears, bile, gastric juice, interstitial fluid, tissue biopsy or epithelial cells, oral swab, nasal swab, aqueous humor, amniotic fluid, pleural fluid or breath of the subject; Preferably, the sample comprises blood, plasma, serum, tissue biopsy or epithelial cells; Preferably, the sample is plasma; Preferably, the sample is blood.

8. A product, characterized in that The product includes a substance for detecting GLUL markers; Preferably, the products include products for diagnosing or assisting in diagnosing whether the sample to be tested is a heart failure sample, products for diagnosing or assisting in diagnosing whether the subject to be tested is a heart failure patient, products for predicting or assisting in predicting whether the sample to be tested is a heart failure sample, and products for predicting or assisting in predicting whether the subject to be tested is a heart failure patient.

9. The product according to claim 8, characterized in that The substance for detecting GLUL markers includes a substance for detecting gene expression level or a substance for detecting protein level; Preferably, the product includes reagents, kits, test strips, nucleic acid membrane strips, chips, primers, and probes; Preferably, the subject includes a human or a non-human mammal; Preferably, the reagents include reagents for detecting the presence, absence and / or amount of GLUL genes, fragments and proteins in a sample by PCR reaction, RT-PCR derivatization reaction, 3SR amplification, LCR, SDA, NASBA, TMA, SYBR Green, TaqMan probe, molecular beacon, double hybridization probe, composite probe, ISH, microarray, Southern blot, Northern blot, multi-analyte spectrum test, enzyme-linked immunosorbent assay (ELISA), radioimmunoassay, immunofluorescence assay, enzyme immunoassay, immunoprecipitation assay, chemiluminescence assay, immunohistochemistry assay, dot blot assay or slot blot assay; Preferably, the kit includes a gene detection kit and a protein detection kit; Preferably, the gene detection kit comprises primers, reagents or chips for detecting the transcription level of the GLUL gene; Preferably, the protein detection kit comprises reagents, chips, antibodies and ligands for detecting the protein level of GLUL expression.

10. A method for screening drugs for treating, preventing or alleviating heart failure for non-therapeutic purposes, characterized in that: The method comprises the steps of applying a candidate drug to in vitro cardiomyocytes or tissues, and the method detects the expression of GLUL after the candidate drug is administered; Preferably, the expression of GLUL includes the transcription level of the GLUL gene or the protein level of GLUL.

Citation Information

Patent Citations

  • Use of glutamine synthetase for treating hyperammonemia

    CN111093641A

  • Glutamine synthetase as marker of pancreatic ductal adenocarcinoma and application of glutamine synthetase

    CN115932262A

  • A method for the diagnosis or prognosis of an advanced heart failure

    WO2011044927A1